Specificity of Protection from EAE After Injection with Myelin-derived Sulfatide a
Treatment . | MOG35-55/CFA/PT . | Incidence (no. of mice [maximum score]) . | Mean maximum score . | Mean day of onset . |
|---|---|---|---|---|
| C57BL/6 | ||||
| PBS | + | 24/24 [2(2), 7(3), 12(4), 3(5)] | 3.7 | 12.9 |
| Sulfatide (d 0) | + | 13/23b[10(0), 8(2), 1(3), 1(4)] | 1.8 | 18 |
| Sulfatide (d − 7) | + | 4/6 [1(2), 3(3)] | 1.9 | 15.4 |
| Sulfatide (d + 7) | + | 2/6 [2(2)] | 0.7 | 16.1 |
| GM1 | + | 11/11 [2(2), 5(3), 4(4)] | 3.2 | 16 |
| Sphingomyelin | + | 4/4 [2(2), 2(4)] | 3.0 | 13.3 |
| β-GalCer | + | 6/6 [1(2), 1(3), 2(4), 2(5)] | 4.0 | 14.3 |
| Sulfatide | − | 0/5 | ||
| C57BL/6 – CD1dKO | ||||
| PBS | + | 7/7 [2(2), 2(3), 2(4), 1(5)] | 2.9 | 13 |
| Sulfatide | + | 8/8
[1(2), 3(3), 3(4)] | 3.0 | 12.8 |
Treatment . | MOG35-55/CFA/PT . | Incidence (no. of mice [maximum score]) . | Mean maximum score . | Mean day of onset . |
|---|---|---|---|---|
| C57BL/6 | ||||
| PBS | + | 24/24 [2(2), 7(3), 12(4), 3(5)] | 3.7 | 12.9 |
| Sulfatide (d 0) | + | 13/23b[10(0), 8(2), 1(3), 1(4)] | 1.8 | 18 |
| Sulfatide (d − 7) | + | 4/6 [1(2), 3(3)] | 1.9 | 15.4 |
| Sulfatide (d + 7) | + | 2/6 [2(2)] | 0.7 | 16.1 |
| GM1 | + | 11/11 [2(2), 5(3), 4(4)] | 3.2 | 16 |
| Sphingomyelin | + | 4/4 [2(2), 2(4)] | 3.0 | 13.3 |
| β-GalCer | + | 6/6 [1(2), 1(3), 2(4), 2(5)] | 4.0 | 14.3 |
| Sulfatide | − | 0/5 | ||
| C57BL/6 – CD1dKO | ||||
| PBS | + | 7/7 [2(2), 2(3), 2(4), 1(5)] | 2.9 | 13 |
| Sulfatide | + | 8/8
[1(2), 3(3), 3(4)] | 3.0 | 12.8 |
Groups of mice were injected i.p. with 20 μg of sulfatide, mono-GM1, sphingomyelin, β-GalCer, or PBS/vehicle only. On the same day (d 0), injected mice were immunized s.c. with MOG35-55/CFA/PT for the induction of EAE. Sulfatide was also injected either 7 d prior to (d − 7) or after (d + 7) the immunization with MOG35-55/CFA/PT. The incidence, mean maximum score, and mean day of onset of clinical EAE is shown.
P < 0.0001.